公開日期 | 標題 | 作者 | 來源出版物 | scopus | WOS | 全文 |
---|---|---|---|---|---|---|
2017 | Real-world experience of afatinib as a first-line therapy for advanced EGFR mutation-positive lung adenocarcinoma | SHENG-KAI LIANG ; MIN-SHU HSIEH ; MENG-RUI LEE ; LI-TA KENG ; JEN-CHUNG KO ; JIN-YUAN SHIH | Oncotarget | 55 | 52 | |
2022 | Recalibrating Risk Prediction Models by Synthesizing Data Sources: Adapting the Lung Cancer PLCO Model for Taiwan | Chien, Li-Hsin; Chen, Tzu-Yu; Chen, Chung-Hsing; KUAN-YU CHEN ; Hsiao, Chin-Fu; Chang, Gee-Chen; Tsai, Ying-Huang; Su, Wu-Chou; Huang, Ming-Shyan; Chen, Yuh-Min; CHIH-YI CHEN ; SHENG-KAI LIANG ; CHUNG-YU CHEN ; Wang, Chih-Liang; Hung, Hsiao-Han; Jiang, Hsin-Fang; Hu, Jia-Wei; Rothman, Nathaniel; Lan, Qing; Liu, Tsang-Wu; Chen, Chien-Jen; PAN-CHYR YANG ; Chang, I-Shou; Hsiung, Chao A | Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology | 1 | 0 | |
2017 | Significant clinical factors associated with long-term mortality in critical cancer patients requiring prolonged mechanical ventilation | LI-TA KENG ; KUEI-PIN CHUNG ; SHU-YUNG LIN ; SHENG-KAI LIANG ; Cheng J.-C.; I-CHUN CHEN ; YEN-FU CHEN ; Chang H.-T.; CHIA-LIN HSU ; JIH-SHUIN JERNG ; HAO-CHIEN WANG ; PING-HUNG KUO ; HUEY-DONG WU ; JIN-YUAN SHIH ; CHONG-JEN YU | Scientific Reports | 7 | 7 | |
2021 | Treatment Options of First-Line Tyrosine Kinase Inhibitors and Subsequent Systemic Chemotherapy Agents for Advanced EGFR Mutant Lung Adenocarcinoma Patients: Implications From Taiwan Cancer Registry Cohort | SHENG-KAI LIANG ; LI-TA KENG ; CHIA-HAO CHANG ; Wen, Yueh-Feng; MENG-RUI LEE ; CHING-YAO YANG ; JANN-YUAN WANG ; JEN-CHUNG KO ; JIN-YUAN SHIH ; CHONG-JEN YU | Frontiers in Oncology | 2 | 3 | |
2016 | Vorinostat enhances the cisplatin-mediated anticancer effects in small cell lung cancer cells | Pan, Chun-Hao; Chang, Ying-Fang; Lee, Ming-Shuo; Wen, B-Chen; JEN-CHUNG KO ; SHENG-KAI LIANG ; Liang, Mei-Chih | BMC cancer | 35 | 32 |